, even in cases with only a minor population of NPM1 mutant alleles present in the sample (approx. 5-10%) (Figure 1b , lower panel), reaction with the LNA very efficiently blocks wt-NPM1 amplification (Figure 1b , upper panel) and allows unambiguous identification of the NPM1 mutation (TCTG) present in the sample in the consecutive direct sequence analysis ( Figure 1c , upper panel). Amplification without the LNA did not allow the identification of the NPM1 mutation in this case (Figure 1c, lower panel) . We further tested the ability to detect minor populations of mutant cells. LNA-clamped PCR products were generated from 1:100 to 1:1000 dilutions of different mutants in excess of the wt-sequence, and were detected using either Genescan fragment analysis or low-density array detection (Chipron, Berlin, Germany). High-resolution fragment analysis differentiates easily between the wt and the mutant band, making this procedure a simple and rapid assay for detection of MRD. Also, the solid-phase hybridization on the array was able to detect the variant as exemplified for type A and B mutations (Figure 1d ), and thus might further enhance the identification of the mutation.
The actual detection level is clearly lower than achievable with other procedures, 6 and thus might be insufficient to perform MRD analysis with high sensitivity, detecting cell populations far below 1/1000 cells. However, the flexibility of the assay makes it especially suitable for rapid assessment of the presence of mutations in follow-up samples. This is of major importance in those cases in which only material after start of treatment is available, or when the precise type of mutation is unknown, because initial diagnosis and MRDassessment were performed in different laboratories. In addition, this assay might help to identify the precise mutation type present in those 20% not having mutation Type A, especially for the design of real-time PCR primers and probe sets for MRD quantification. 6 Taken together, the simple procedure described here enables the rapid assessment of NPM1 mutations with a sensitivity of 1/100 to 1/1000 and avoids the necessity of cloning or other steps to unambiguously identify NPM1 alterations. The assay was able to detect more than 30 different NPM1 mutations, thus seems to work with the vast majority of mutations reported so far. It appears to represent a versatile tool for NPM1 mutation detection and might be combined with other assays like fragment analysis or real-time PCR to improve MRD detection. This is especially relevant in those cases having not one of the typical mutations (Type A, B, D), where establishing an individual real-time PCR assay might be too time consuming in the clinical situation. 4, 6 Serial analyses of CEBPA and NPM mutations showed that the mutation disappeared at complete remission, but the same mutation reappeared at relapse. 4, 5, 7 None of the AML patients without these mutations at presentation acquired them at relapse. 4, 5, 7, 8 This phenomenon suggests that modern genetic characterization of AML should be integrated into any salient analysis of mutational status. Cluster regions of NPM and CEBPA mutations have been clearly identified. Two categories of distinct CEBPA mutations are reported: out-of-frame insertion/deletion (I/D) and in-frame I/D, often in nucleotides (nts) 640-880 of the N-terminal and nts 1500-1600 of C-terminal regions, respectively. 3 The hotspots of NPM mutations are located in nt959 or 965 of exon 12, all of which are four-nucleotide insertion and causing a frameshift that lead to a five-amino-acid longer product with the new C-terminal VSLRK. 2 In this communication, we describe a novel, rapid and reproducible method for simultaneous screening of the CEBPA and NPM mutations using multiplex polymerase chain reaction (PCR) coupled with capillary electrophoresis and fluorescence detection. Moreover, this method could be used for monitoring disease status after treatment. Based on our previously reported CEBPA and NPM sequences and their mutations, 4, 5 we designed four pairs of primers (Table 1 ) covering all those mutations using PrimerQuest software (Integrated DNA Technologies, Coralville, IA, USA). Each one of the primer pairs were labeled with appropriate fluorescence. To obtain the best efficacy, optimal primer concentrations and PCR condition for multiplex PCR were adjusted and stated in Table 1 . The detected amplicons were subsequently diluted in distilled water and mixed with Table 2 GeneScanner and mutation patterns for CEBPA and NPM in AML patients Sequence numbering and mutation names for NPM were referred to reference 2. The mutations have been reported previously.
Letters to the Editor deionized formamide and GENESCAN-400HD (ROX) size markers (Applied Biosystems, Foster City, CA, USA). These mixtures were then electrophoresed on an ABI Prism 3100 Genetic Analyzer (Applied Biosystems). After electrophoresis, the fluorescence signals were analyzed using GeneScan 3.1 software (Applied Biosystems) (Figure 1 ). In the meantime, the CEBPA and NPM sequences were determined using the BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems) on an automated ABI 3730 Genetic Analyzer as reported previously. 4, 5 Of the 99 AML patients studied, 30 (30.3%) had TAD2 ( þ 6 bp) pattern; further direct sequencing confirmed this mutation was TAD2-C, a polymorphism with insertion of GCACCC in genomic DNA reported in our previous study. 5 One of them also had simultaneous another abnormal TAD2 ( þ 12 bp), which was an in-frame mutation with insertion of duplicates of GCACCC, probably generating from TAD2-C. Further sequential analysis of this patient revealed that this mutation remained positive at complete remission, suggesting TAD2 ( þ 12 bp) was a polymorphism, too.
Excluding the two polymorphisms mentioned above, 19 distinct CEBPA mutations and five NPM mutations were detected in 13 (13%) and 20 (20%) patients, respectively (Table 2 and Supplementary Figure 1) . None had both mutations, confirming that the two mutations were mutually exclusive in AML patients. Among the 53 patients with a normal karyotype, 31 (58%) showed either CEBPA or NPM mutations. Out of these 19 CEBPA mutations and five NPM mutations, 15 and two, respectively, have never been reported before ( Table 2 ). All of the NPM mutations could be detected using either direct sequencing or multiplex PCR; however, two of the CEBPA mutations could be detected only by sequencing, but not by multiplex PCR. One is CEBPA nt1489(C-G) in patient 18 who bore additional CEBPA nt864/865( þ C), and the other is CEBPA nt917/918( þ C) in patient 90 who harbored additional CEBPA nt1535/1536( þ 36 bp). Consequently, for this cohort of AML patients, the overall sensitivity of multiplex PCR for NPM mutation was 100% (20/20) and that for CEBPA mutation was up to 90% (17/19). If considering the AML patients with CEBPA mutation, the sensitivity was 100% (13/13). The specificities for both were up to 100%. The limitation of multiplex PCR in CEBPA nt917/918( þ C) detection was owing to its being in the region where the reverse primer for TAD1 located. We attempted to redesign another reverse primer 3 0 to this mutation, but failed owing to an abundance of GC-rich sequences downstream of this primer. PCR products from the redesigned primers were thus too large to interpret precisely mutations with 1 bp difference. Another limitation of this multiplex PCR was the detection of base substitution. However, CEBPA mutations with base substitution were few and most of them were polymorphism. Thus, despite some limitations, this novel one-step multiplex PCR in this study is able to detect distinct CEBPA mutation up to 90%, making it effective for routine screening. With respect to the CEBPA mutations reported to date worldwide, the sensitivity could be 93.6% (Supplementary Figure 2) . Accordingly, for those AML patients with a normal karyotype and showing neither CEBPA nor NPM mutation by multiplex PCR, we can further perform direct sequencing for CEBPA gene to avoid misdiagnosis.
Given previous reports outlining the therapeutic significance of monitoring CEBPA and NPM mutations during clinical follow-up, 4 ,5 detection of these mutations for monitoring early relapse subsequent to complete remission is important. To assess the minimum detection limit, serial dilutions of mutant with normal DNA, accounting for 2, 5, 10, 20, 40 and 80%, were prepared from AML patients with homozygous bZIP-D mutant (nt 1520/1521, þ 21 bp, see Lin et al. 5 ) for bZIP region analysis in three separate experiments. After PCR reaction, the ratios of mutant fragments to normal analogs (calculated from peak areas) were compared. The mutant percentage was calculated according to the following equation: %Mutant ¼ (MA)/ (NA þ MA) Â 100%, with NA and MA the peak areas for the normal and mutant alleles, respectively. The correlation coefficient for the relationship between calculated and expected value was 0.99, and this novel method can detect mutant DNA percentages down to 5% of total DNA (Supplementary Figure 3) .
The within-run reproducibility for peak areas at the four regions was determined in AML patients with heterozygous mutant alleles by making nine replicate measurements of the same PCR products; the coefficient of variations (CVs) for the TAD1, TAD2, bZIP and NPM regions was 0.6, 0.5, 0.9 and 0.7%, respectively. The between-run reproducibility was also determined for the same samples by performing five separate PCR analyses, with CVs for the TAD1, TAD2, bZIP and NPM regions of 5.3, 1.5, 3.7 and 1.8%, respectively. For early detection of relapse in AML patients after complete remission, the CEBPA mutations were serially studied in four individuals by using simple PCR with significant primer pair. We found that the abnormal band at presentation disappeared during complete remission, and reappeared on relapse (Supplementary Figure 4) .
Given the fact that CEBPA and NPM mutations are currently the most frequently reported genetic aberrations in AML, and in light of their potential prognostic significance, we believe that inclusion of this multiplex PCR assay in diagnostic evaluations of AML may improve the efficacy of routine genetic characterization and allow assignment of patients to better-defined risk categories. This is a quite simple and reproducible method, which shows high sensitivity and apparent accuracy and offers, to a degree, the ability to detect early relapse post-therapy, although not to very low level for minimal residual disease detection. 9, 10 Myeloproliferative disorders (MPD) are a heterogeneous group of clonal hematopoietic stem cell malignancies that classically include four related entities: chronic myelogenous leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IM). With the exception of IM, all of these disorders are characterized by increased hematopoiesis and overproduction of blood elements, with the predominance of one myeloid lineages. In CML, the granulocytic lineage is the most hyperplastic, whereas the erythroblastic and megakaryocytic lineage are predominantly involved in PV and ET, respectively. These diseases are characterized by a clonal hematopoiesis, which involve the hematopoietic stem cells, as all myeloid lineages are monoclonal.
A hallmark of MPD is the independence or hypersensitivity of hematopoietic progenitors to numerous cytokines. In PV, one of the most relevant characteristics is endogenous erythroid colony formation (eBFU-E). Erythroid progenitor cells proliferate in semisolid cultures in the absence of exogenous erythropoietin (EPO). Similar growth pattern is observed in a significant proportion of patients with ET and IM, but never in healthy individuals. Some studies have revealed that erythroid colony formation (BFU-E) in PV are hypersensitive not only to EPO but also to several other hematopoietic growth factors, including interleukin (IL)-3, stem cell factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), insulin-like growth factor and thrombopoietin (TPO). Several studies have revealed that megakaryocytic colony formation (CFU-Mk) is growth factorsindependent in the majority of ET patients. This endogenous megakaryocytic colony formation (eCFU-MK) has also been shown, but in a lesser degree, in some PV, IM and even in CML, but not in reactive thrombocytosis.
Recently, the existence of an activating mutation of Janus kinase 2 (JAK2) tyrosine kinase in granulocytes has been reported in a high proportion of patients with MPD 1-4 (80% of PV, 50% of ET and 50% of IM). JAK2 is a cytoplasmatic tyrosine kinase with a key role in signal transduction from diverse cytokines and growth factors (extracellular ligands), including those for IL-3, IL-5, EPO, GM-CSF, granulocyte colonystimulating-factor receptor (G-CSF) and TPO, all of which play a major role in myeloid development. The JAK2 V617F is located in the pseudokinase domain of the JAK2 gene, a region that inhibits JAK2 kinase activity. This mutation in the pseudokinase autoinhibitory domain results in a constitutive kinase activity and induces cytokine hypersensitivity or independence of factor-dependent cell lines. [1] [2] [3] [4] On the other hand, Lu et al. 5 have shown that coexpression of the JAK2 V617F mutant kinase with a homodimeric type I cytokine receptor (such as the EPO receptor, the TPO receptor or the G-CSF receptor) is necessary for transformation of hematopoietic cells to growth factor independence and for hormone-independent activation of JAK-STAT signaling pathway. This phenomenon reveals the molecular basis for the prevalence of JAK2 V617F in diseases of myeloid lineage cells that express these type I cytokine receptors, but not in lymphoid lineage cells that do not.
The incidence of JAK2 mutation in ET patients ranges from 25 to 57% depending on the study. These variation is likely owing to the sensitivity of the assay used to detect JAK2 V617F and the cell type analyzed (variabilty of the implication of different myeloid lineages in ET). In the majority of reports, the JAK2 V617F has been described in whole blood or isolated granulocytes, whereas limited information to referred to platelets and no data have been reported in isolated megakaryocytes. 6 The aim of the present study was to analyze the presence of the JAK2 V617F in megakaryocytic cells obtained from peripheral blood in vitro cultures and in the remaining myeloid cells: peripheral blood granulocytes and platelets, as well as erythroid and granulomonocyte colonies obtained from peripheral blood in vitro cultures of patients with ET.
We have evaluated six newly diagnosed ET patients according to the WHO's diagnostic criteria. Written informed consent was obtained from every patient. All the assays were determined at diagnosis.
In vitro cultures were performed as reported previously. 7 Twenty milliliter of venous blood was collected in ethylendiaminetetraacetic acid and immediately processed. Neutrophils were isolated by Lymphoprep (1077 g/ml) density gradient, followed by dextran sedimentation. Total RNA was isolated from granulocytes or platelets using guanidinium thiocyanate method (Ultraspec; Biotecx Laboratories, Houston, TX, USA). cDNA was reverse transcribed from 1 mg of total RNA with Murine Moloney Leukemia Virus reverse transcriptase (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the standard procedures with random hexamers. Isolated colonies from in vitro cultures were carefully aspirated and washed with phosphate-buffered saline. RNA
